NCNA
NuCana Plc
NASDAQ · Healthcare · Biotechnology · GB
$0.98
−1.30%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.00
From 52W high−80.73%
Volume22328.00
Market cap$4.07M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.00
From 52W high
−80.73%
Volume
22328.00
Market cap
$4.07M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
1.1x
P/E (TTM)
—
RSI (14)
32.2
MomentumView details →
1D Return
−1.30%
YTD Return
−72.22%
SummaryUpdated Jun 1, 2026
NuCana plc (NASDAQ:NCNA) is a clinical-stage biopharmaceutical company founded in 1997 and headquartered in Edinburgh, United Kingdom. The company went public in September 2017, transitioning from its former name NuCana BioMed Limited. NuCana focuses on developing innovative cancer treatments using its proprietary ProTide technology platform, with multiple drug candidates currently progressing through various phases of clinical trials for treating solid tumors and blood cancers.
Similar companies
Latest newsMore news →